Fig. 7: STEER-HS38 improves myocardial reperfusion outcomes. | Nature Communications

Fig. 7: STEER-HS38 improves myocardial reperfusion outcomes.

From: Identification of splenic IRF7 as a nanotherapy target for tele-conditioning myocardial reperfusion injury

Fig. 7

a Representative TTC-stained slices of mice hearts subjected to 60 min of ischemia followed by 24 h of reperfusion, with the administration of free HS38 (dispersed in 2% F68) or STEER-HS38, or no treatment. Quantification of infarct size according to TTC staining (n = 6 mice per group). b Serum LDH concentrations in mice at 24 h after IR injury with no treatment, free HS38 (dispersed in 2% F68) or STEER-HS38 (n = 6 mice per group). c Representative TUNEL staining of mice at 24 h after IR injury with no treatment, free HS38, or STEER-HS38 and quantification of TUNEL+ cells (n = 6 mice per group). d Representative M-mode echocardiographic images from mice at 1 w after IR injury. e Quantifications of ejection fraction, fractional shortening, LVEDV and LVESV at 1 w after IR injury (n = 8 mice per group). LVEDV, left ventricle end-diastolic volume; LVESV, left ventricle end-systolic volume. f Representative M-mode echocardiographic images from mice at 6 w after IR injury. g Quantifications of ejection fraction, fractional shortening, LVEDV and LVESV at 6 w after IR injury (n = 8 mice per group). h Representative images of Masson trichrome staining of heart at 6 w after IR injury. i, j Quantitative measurement of average wall thickness and fibrotic area (%) (n = 8 mice per group). The data are expressed as mean ± s.d. Statistical analyses were conducted by one-way ANOVA with Tukey’s post hoc test. Source data are provided as a Source Data file.

Back to article page